Recent

% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

biotechinvest1077 3 posts  |  Last Activity: Apr 3, 2016 2:50 PM Member since: May 27, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Here's your example Mudbug021

    by pert.near Apr 3, 2016 9:35 AM
    biotechinvest1077 biotechinvest1077 Apr 3, 2016 2:50 PM Flag

    JimmyGreaves,

    You said, "Not really. The P2s were pretty much done, S had already ACED them, by curing every patient. I think more interesting may be that there never really was a P3, as such."

    While the first part of your statement is true, the last part isn't. You probably got the last part about Sovaldi never really having a Phase 3 from Holdencf. A few months back he wrote,

    "(GILD) Pharmasset still collecting data in its P3 trial. They received marketing labeling approval after P2. For an unmet medical need with a statistically robust P2 data set don't need P3. ARWR currently enrolling and treating or have treated 350 patients. That number will increase as P2 progresses and is more than enough to secure an FDA labeling approval. Can start marketing with stated commitment to conduct post-marketing P3 as the drug rolls out...."

    But the fact is GILD's Sovaldi was only approved after four (4) Phase 3 trials. Holden often shoots from the hip. He is prone to making grand claims that are factually wrong.

  • biotechinvest1077 biotechinvest1077 Mar 7, 2016 8:00 PM Flag

    For me the key question relates to whether or not Arbutus's lead HBV compound effectively targets integrated DNA.

    This is the 64,000 dollar question as it directly impacts ARWR's current 2 year lead in the clinic.

    So the question is: "Does Arbustus's ARB-1467, their lead HBV compound currently in Phase 2 for HBV, effectively target iDNA?"

  • biotechinvest1077 by biotechinvest1077 Mar 1, 2016 12:43 PM Flag

    CYTK seems cheap w/ Omecantiv having legit blockbuster potential. What is Amgen waiting for?

    Sentiment: Strong Buy

OGXI
0.97-0.03(-3.00%)May 27 3:57 PMEDT